Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin gets USFDA nod...

    Lupin gets USFDA nod for generic version of Levoxyl tablets to treat hypothyroidism

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-02T10:00:49+05:30  |  Updated On 17 Aug 2021 12:10 PM IST

    The product is a generic version of King Pharmaceuticals Research and Development LLC's Levoxyl tablets in same strengths, Lupin said.


    New Delhi: Drug firm Lupin on Friday said it has received approval from the US health regulator to market its generic Levothyroxine Sodium tablets in the American market.


    The tablets are indicated for the treatment of hypothyroidism and pituitary thyrotropin suppression, Lupin said in a statement.


    The company has received approval from the United States Food and Drug Administration (USFDA) for its supplemental abbreviated new drug application (ANDA) to market its Levothyroxine Sodium tablets in the strengths of 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, it added.


    Read Also: Lupin gets USFDA nod for a generic equivalent of UNITHROID to treat thyroid


    The product is a generic version of King Pharmaceuticals Research and Development LLC's Levoxyl tablets in same strengths, Lupin said.


    With this approval, the company's product is now a generic version of ABBVIE Inc's Synthroid tablets, Jerome Stevens Pharmaceuticals Inc's Unithroid tablets and Levoxyl tablets of King Pharmaceuticals Research and Development LLC, it added.


    It is the only product approved with FDA's new narrow therapeutic index guidance for Levothyroxine, Lupin said.


    The cumulatively Levothyroxine Sodium tablets USP had annual sales of around USD 2,581 million in the US, Lupin said.


    Read Also: Lupin launches generic Levothyroxine Sodium tablets

    genericgeneric drughypothyroidism tabletsKing PharmaLevothyroxineLevothyroxine Sodium tabletsLevoxyl tabletsLupinpituitary thyrotropin suppressionTag Jerome Stevens PharmaUnited States Food and Drug AdministrtionUS health regulatorUSFDAUSFDA nod
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok